A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

NCT04383067 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Metastatic Urothelial Carcinoma

Interventions

PROCEDURE: Tumor Infiltrating Lymphocytes (TIL)
DRUG: Proleukin

Sponsor

Sheba Medical Center